search
Back to results

Dopaminergic Effects on Cortical Function in Tourette's (Levodopa Protocol) (TSfMRI)

Primary Purpose

Tourette Syndrome

Status
Completed
Phase
Phase 1
Locations
United States
Study Type
Interventional
Intervention
levodopa solution 2mg/ml for i.v. use
placebo
Sponsored by
Washington University School of Medicine
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional other trial for Tourette Syndrome focused on measuring Tourette Syndrome, fMRI, levodopa, working memory, dopamine

Eligibility Criteria

18 Years - 55 Years (Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • Age 18-55.
  • Tic subjects must meet DSM-IV-TR criteria for a chronic tic disorder.
  • Controls are matched for age (within 4 years), sex, handedness (right-handed, non-right-handed), and education (within 2 years), and if possible for race and ethnicity

Exclusion Criteria:

  • Inability to give competent informed consent.
  • Lactation, pregnancy or possibility of pregnancy.
  • Contraindication to MRI (pacemaker; nontrivial metallic foreign bodies; significant claustrophobia).
  • Contraindication to levodopa or carbidopa (known allergy).
  • Significant neurological disease (not counting the tic disorder).
  • Current renal, cardiac or hepatic disease that would make study participation less safe.
  • Head injury with loss of consciousness for more than 5 minutes or with neurological sequelae.
  • Lifetime history of serious lifetime psychopathology or substance abuse. (Specific exclusions are: lifetime diagnosis of mental retardation, autism, psychosis, mania, somatization disorder, panic disorder, social phobia [excludes symptoms present only when treated with a neuroleptic], anorexia nervosa or bulimia, drug or alcohol dependence, antisocial personality disorder, or dementia, or current major depression.)
  • Depot neuroleptics in the past 6 months.
  • Other antipsychotics within the past 2 weeks.
  • Behavioral therapy for Tics of OCD sx in the past 2 weeks.
  • For one half of the subjects in each diagnostic group: any brain-active medications within the past 2 weeks. For the remaining subjects: neuroactive medications in the past 2 weeks other than SSRIs, alpha-2 agonists, norepinephrine reuptake inhibitors, or clonazepam.
  • Additional exclusions for controls: No history of tic disorder, OCD or ADHD. If under age 25, no first-degree relative with a tic disorder. No exposure to neuroleptics in the past year and none ever for a period exceeding a week.

Sites / Locations

  • Washington Universisty School of Medicine,

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Placebo Comparator

Arm Label

levodopa solution 2mg/ml for i.v. use

Placebo

Arm Description

levodopa solution in saline, given intravenously, dosed as per "final protocol" in Black et al 2003.

normal saline i.v.

Outcomes

Primary Outcome Measures

BOLD (blood oxygen-level dependent) fMRI (functional magnetic resonance imaging) response to a working memory task

Secondary Outcome Measures

serum prolactin concentration

Full Information

First Posted
March 5, 2008
Last Updated
February 8, 2018
Sponsor
Washington University School of Medicine
Collaborators
National Institute of Mental Health (NIMH)
search

1. Study Identification

Unique Protocol Identification Number
NCT00634556
Brief Title
Dopaminergic Effects on Cortical Function in Tourette's (Levodopa Protocol)
Acronym
TSfMRI
Official Title
Dopaminergic Effects on Cortical Function in Tourette's (Levodopa Protocol)
Study Type
Interventional

2. Study Status

Record Verification Date
February 2018
Overall Recruitment Status
Completed
Study Start Date
February 2006 (undefined)
Primary Completion Date
October 2010 (Actual)
Study Completion Date
October 2010 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Washington University School of Medicine
Collaborators
National Institute of Mental Health (NIMH)

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Dr. Kevin J. Black at Washington University is conducting a study to learn whether we can use MRI scans to test dopamine function in the brain and to determine whether the brain performs memory tasks differently in Tourette Syndrome (TS). TS is a movement disorder characterized by vocal tics (sounds) and motor tics (movements). We will measure how and where brain activity changes using magnetic resonance imaging (MRI) scans during memory tasks and after taking levodopa. Levodopa is a drug commonly used for the treatment of Parkinson's disease (PD), a very different movement disorder.
Detailed Description
Clinical observations suggest that in TS there is abnormal function in the brain's motor system that can be modified by manipulating dopamine. My colleagues and I have hypothesized that nonmotor brain systems may also show dopamine-sensitive functional abnormalities. Recently we tested this hypothesis using functional magnetic resonance imaging (fMRI). A cognitive task involving working memory (WM) produced excessive activation of several brain regions in TS subjects compared to controls, but this excessive activation normalized after administering the dopamine precursor levodopa (Hershey et al, 2004). We can state the following focused hypotheses and corresponding specific aims: (1) In TS, normal performance during a working memory (WM) task requires greater activation of specific brain regions (parietal cortex, medial frontal cortex and thalamus) than in control subjects, and this excess fMRI response is reduced (improved) by exogenous levodopa. (2) These fMRI results in TS relate specifically to WM, to TS, and to dopamine receptor activation, rather than to non-WM components of the cognitive task, comorbidity, placebo effects, or other confounds. Specific Aim 1. Test whether the preliminary fMRI results generalize to a larger and more representative sample of adults with TS. Specific Aim 2. Clarify the variables that interact to produce the differential fMRI responses to a WM task and levodopa observed in TS subjects vs controls. 2a. Task components. Control for non-WM components of the task and delineate a "dose-response" curve for effects of WM load on fMRI responses. 2b. Clinical variables. Test whether the fMRI results in our preliminary data are associated with TS itself rather than with comorbid conditions, treatment history, demographic variables, or state variables such as current tic severity / tic suppression. 2c. Pharmacology. Test whether the post-levodopa changes in WM-related fMRI signal relate specifically to levodopa plasma concentration (rather than practice effects, placebo effects, or passage of time) and are replicated by a nonselective dopamine receptor agonist or by a dopamine D2/D3/D4 agonist.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Tourette Syndrome
Keywords
Tourette Syndrome, fMRI, levodopa, working memory, dopamine

7. Study Design

Primary Purpose
Other
Study Phase
Phase 1
Interventional Study Model
Factorial Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
49 (Actual)

8. Arms, Groups, and Interventions

Arm Title
levodopa solution 2mg/ml for i.v. use
Arm Type
Experimental
Arm Description
levodopa solution in saline, given intravenously, dosed as per "final protocol" in Black et al 2003.
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
normal saline i.v.
Intervention Type
Drug
Intervention Name(s)
levodopa solution 2mg/ml for i.v. use
Other Intervention Name(s)
L-DOPA, L-3,4-dihydroxyphenylalanine
Intervention Description
2mg/mL in normal saline
Intervention Type
Drug
Intervention Name(s)
placebo
Other Intervention Name(s)
NaCl 0.9% in water
Intervention Description
normal saline
Primary Outcome Measure Information:
Title
BOLD (blood oxygen-level dependent) fMRI (functional magnetic resonance imaging) response to a working memory task
Time Frame
From about 30 to 120 minutes after infusion begins
Secondary Outcome Measure Information:
Title
serum prolactin concentration
Time Frame
approximately 2 hours after infusion begins

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
55 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Age 18-55. Tic subjects must meet DSM-IV-TR criteria for a chronic tic disorder. Controls are matched for age (within 4 years), sex, handedness (right-handed, non-right-handed), and education (within 2 years), and if possible for race and ethnicity Exclusion Criteria: Inability to give competent informed consent. Lactation, pregnancy or possibility of pregnancy. Contraindication to MRI (pacemaker; nontrivial metallic foreign bodies; significant claustrophobia). Contraindication to levodopa or carbidopa (known allergy). Significant neurological disease (not counting the tic disorder). Current renal, cardiac or hepatic disease that would make study participation less safe. Head injury with loss of consciousness for more than 5 minutes or with neurological sequelae. Lifetime history of serious lifetime psychopathology or substance abuse. (Specific exclusions are: lifetime diagnosis of mental retardation, autism, psychosis, mania, somatization disorder, panic disorder, social phobia [excludes symptoms present only when treated with a neuroleptic], anorexia nervosa or bulimia, drug or alcohol dependence, antisocial personality disorder, or dementia, or current major depression.) Depot neuroleptics in the past 6 months. Other antipsychotics within the past 2 weeks. Behavioral therapy for Tics of OCD sx in the past 2 weeks. For one half of the subjects in each diagnostic group: any brain-active medications within the past 2 weeks. For the remaining subjects: neuroactive medications in the past 2 weeks other than SSRIs, alpha-2 agonists, norepinephrine reuptake inhibitors, or clonazepam. Additional exclusions for controls: No history of tic disorder, OCD or ADHD. If under age 25, no first-degree relative with a tic disorder. No exposure to neuroleptics in the past year and none ever for a period exceeding a week.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Kevin J Black, MD
Organizational Affiliation
Washington Universisty School of Medicine
Official's Role
Principal Investigator
Facility Information:
Facility Name
Washington Universisty School of Medicine,
City
Saint Louis
State/Province
Missouri
ZIP/Postal Code
63110
Country
United States

12. IPD Sharing Statement

Plan to Share IPD
No
IPD Sharing Plan Description
Vital signs IPD are shared at: Siddiqi SH, Creech ML, Black KJ. Orthostatic stability with intravenous levodopa. PeerJ. 2015 Aug 27;3:e1198. doi: 10.7717/peerj.1198. eCollection 2015. PubMed ID: 26336641 There is no plan to share other IPD.
Citations:
PubMed Identifier
15110735
Citation
Hershey T, Black KJ, Hartlein JM, Barch DM, Braver TS, Carl JL, Perlmutter JS. Cognitive-pharmacologic functional magnetic resonance imaging in tourette syndrome: a pilot study. Biol Psychiatry. 2004 May 1;55(9):916-25. doi: 10.1016/j.biopsych.2004.01.003.
Results Reference
background
PubMed Identifier
12865145
Citation
Black KJ, Carl JL, Hartlein JM, Warren SL, Hershey T, Perlmutter JS. Rapid intravenous loading of levodopa for human research: clinical results. J Neurosci Methods. 2003 Jul 15;127(1):19-29. doi: 10.1016/s0165-0270(03)00096-7.
Results Reference
background
Citation
Campbell M, Koller J, Shipley E, Creech M, Hershey T, Black K. Dopaminergic modulation of working memory in Tourette's syndrome [abstract]. J Neuropsychiatry Clin Neurosci 20(2):232, 2008. http://neuro.psychiatryonline.org/article.aspx?articleid=103362
Results Reference
result
Citation
Black KJ, Campbell MC, Koller JM, Schneider B, Hershey T. Dopaminergic modulation of working-memory-related cortical activity in Tourette syndrome. Annual meeting, Society for Neuroscience, Chicago, 20 Oct 2009. http://www.sfn.org/
Results Reference
result
PubMed Identifier
26336641
Citation
Siddiqi SH, Creech ML, Black KJ. Orthostatic stability with intravenous levodopa. PeerJ. 2015 Aug 27;3:e1198. doi: 10.7717/peerj.1198. eCollection 2015.
Results Reference
result
Links:
URL
http://www.nil.wustl.edu/labs/kevin/studies/TS-dopa-fMRI-NIMH.htm
Description
study description
URL
http://www.nil.wustl.edu/labs/kevin/move/ts.htm
Description
Tourette syndrome resources

Learn more about this trial

Dopaminergic Effects on Cortical Function in Tourette's (Levodopa Protocol)

We'll reach out to this number within 24 hrs